U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258160) titled 'Evaluation of the Effect of PRaG-1 on CD8+ Lymphocytopenia in Patients With Solid Tumors' on Nov. 18.
Brief Summary: The goal of this clinical trial is to evaluate the effectiveness of PRaG-1 in improving CD8+ lymphocytopenia in patients with solid tumors who are tumor-free for more than six months after completing radiotherapy and/or chemotherapy. It will also assess the safety of PRaG-1 in these patients. The main questions it aims to answer are:
Does PRaG-1 increase CD8+ lymphocyte counts by more than 25% in this patient population? Does the effect of PRaG-1 maintain when treatment is discontinued? What are the safety and tolerab...